Utah Medical Products Inc (UTMD)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $204.92M
Last updated: Nov 17, 2026 at 11:05 AM ET
Utah Medical Products Inc (UTMD) Financials: Revenue, Profit and Cash Flow
Utah Medical Products reported revenue of $38.52M for the fiscal year ended Dec 31, 2025, down 5.8% from the year before. That year, net income was $11.29M with a net margin of 29.3%, operating cash flow was $14.69M and free cash flow was $14.32M. The quarter ended Sep 30, 2026 had revenue of $8.62M and net income of $2.79M.
Revenue and Margins
The operating margin was 29.6% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue fell from $39.30M, a compound annual decline of 0.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $38.52M | -5.8% | 57.1% | 29.6% | 29.3% |
| Dec 2024 | $40.90M | -18.6% | 59.0% | 33.2% | 33.9% |
| Dec 2023 | $50.22M | -3.9% | 59.8% | 33.4% | 33.1% |
| Dec 2022 | $52.28M | +6.6% | 61.6% | 37.9% | 31.5% |
| Dec 2021 | $49.05M | +16.3% | 63.0% | 38.5% | 30.1% |
| Dec 2020 | $42.18M | -10.1% | 60.6% | 32.5% | 25.6% |
| Dec 2019 | $46.90M | +11.7% | 62.8% | 37.6% | 31.4% |
| Dec 2018 | $42.00M | +1.4% | 62.6% | 44.5% | 44.2% |
| Dec 2017 | $41.41M | +5.4% | 63.7% | 45.9% | 20.5% |
| Dec 2016 | $39.30M | N/A | 60.3% | 41.2% | 30.9% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 18.6% from the year before. In the quarter ended Sep 2026, net income rose 6.1% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.52M | $40.90M | $50.22M | $52.28M | $49.05M | $42.18M | $46.90M | $42.00M | $41.41M | $39.30M |
| Cost of revenue | $16.52M | $16.76M | $20.19M | $20.09M | $18.14M | $16.63M | $17.44M | $15.69M | $15.02M | $15.61M |
| Gross profit | $22.00M | $24.14M | $30.04M | $32.20M | $30.92M | $25.55M | $29.47M | $26.31M | $26.39M | $23.69M |
| Research and development | $668.00K | $813.00K | $560.00K | $493.00K | $526.00K | $486.00K | $483.00K | $454.00K | $447.00K | $475.00K |
| Operating income | $11.40M | $13.59M | $16.78M | $19.79M | $18.88M | $13.71M | $17.63M | $18.70M | $19.01M | $16.19M |
| Net income | $11.29M | $13.87M | $16.64M | $16.47M | $14.79M | $10.80M | $14.73M | $18.55M | $8.51M | $12.13M |
| EBITDA | $14.29M | $16.27M | $23.40M | $27.06M | $26.16M | $20.92M | $24.51M | $22.09M | $21.75M | $19.15M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.62M | $8.53M | $8.72M | $9.04M | $9.81M | $9.95M | $9.71M | $9.16M | $10.01M | $10.40M | $11.34M | $12.33M |
| Gross profit | $4.84M | $4.76M | $5.28M | $4.73M | $5.60M | $5.59M | $5.54M | $5.32M | $5.80M | $6.25M | $6.77M | $7.10M |
| Operating income | $2.79M | $2.65M | $2.56M | $2.44M | $2.61M | $3.20M | $3.15M | $2.93M | $3.34M | $3.44M | $3.88M | $3.94M |
| Net income | $2.79M | $2.69M | $2.60M | $2.56M | $2.63M | $3.05M | $3.04M | $2.90M | $3.56M | $3.45M | $3.96M | $4.29M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded long-term debt of $225.00K by $85.53M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $122.54M | $122.54M | $135.46M | $123.87M | $115.64M | $111.75M | $109.79M | $99.77M | $92.75M | $76.19M |
| Current assets | $97.74M | $96.33M | $106.27M | $89.92M | $73.16M | $62.26M | $54.89M | $60.90M | $49.19M | $34.47M |
| Cash and equivalents | $85.76M | $82.98M | $92.87M | $75.05M | $60.97M | $51.59M | $42.79M | $51.11M | $39.88M | $26.30M |
| Total liabilities | $3.27M | $5.11M | $7.14M | $9.62M | $8.50M | $8.92M | $8.69M | $10.78M | $14.62M | $6.95M |
| Short-term debt | N/A | $56.00K | $47.00K | $54.00K | $52.00K | $41.00K | $38.00K | N/A | N/A | N/A |
| Long-term debt | $225.00K | $282.00K | $295.00K | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Shareholder equity | $119.27M | $117.43M | $128.31M | $114.25M | $107.14M | $102.82M | $101.09M | $88.99M | $78.12M | $69.24M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $128.50M | $124.57M | $124.38M | $122.54M | $121.97M | $120.80M | $122.52M | $122.54M | $129.69M | $130.03M | $135.44M | $135.46M |
| Total liabilities | $5.22M | $2.54M | $4.01M | $3.27M | $3.72M | $3.27M | $5.47M | $5.11M | $5.50M | $5.98M | $7.70M | $7.14M |
| Cash and equivalents | $85.20M | $87.53M | $87.41M | $85.76M | $84.27M | $82.18M | $83.33M | $82.98M | $88.45M | $89.22M | $93.81M | $92.87M |
| Shareholder equity | $123.28M | $122.03M | $120.37M | $119.27M | $118.25M | $117.53M | $117.05M | $117.43M | $124.20M | $124.05M | $127.74M | $128.31M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 97.5% of operating cash flow. Dividends and share repurchases together came to 86.2% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.69M | $14.83M | $22.28M | $21.15M | $21.20M | $20.14M | $17.06M | $16.83M | $16.91M | $14.53M |
| Capital expenditures | $371.00K | $230.00K | $639.00K | $809.00K | $552.00K | $860.00K | $540.00K | $402.00K | $1.60M | $3.29M |
| Free cash flow | $14.32M | $14.60M | $21.64M | $20.34M | $20.65M | $19.28M | $16.52M | $16.43M | $15.31M | $11.23M |
| Dividends paid | $3.98M | $4.26M | $4.28M | $3.16M | $11.46M | $4.12M | $4.11M | $4.03M | $2.96M | $3.92M |
| Share repurchases | $8.36M | $19.97M | $0 | $2.50M | $0 | $6.98M | $398.00K | $1.21M | $0 | N/A |
| Investing cash flow | -$371.00K | -$208.00K | -$639.00K | -$818.00K | -$552.00K | -$860.00K | -$21.54M | $534.00K | -$1.60M | -$3.30M |
| Financing cash flow | -$12.34M | -$23.84M | -$4.17M | -$5.48M | -$10.90M | -$10.73M | -$4.23M | -$4.78M | -$2.65M | -$6.34M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.50M | $1.38M | $3.11M | $3.48M | $3.88M | $2.87M | $4.46M | $2.94M | $3.86M | $2.76M | $5.28M | $5.33M |
| Capital expenditures | $236.00K | $134.00K | $130.00K | $109.00K | $27.00K | $51.00K | $184.00K | $9.00K | $89.00K | $110.00K | $22.00K | $90.00K |
| Free cash flow | $3.26M | $1.25M | $2.98M | $3.37M | $3.85M | $2.82M | $4.28M | $2.93M | $3.77M | $2.65M | $5.25M | $5.24M |
Frequently Asked Questions About UTMD
What is Utah Medical Products' annual revenue?
Utah Medical Products reported revenue of $38.52M for the fiscal year ended Dec 31, 2025.
How fast is Utah Medical Products' revenue growing?
Revenue was down 5.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -9.7%.
Is Utah Medical Products profitable?
Yes. Utah Medical Products reported net income of $11.29M for the fiscal year ended Dec 31, 2025, with a net margin of 29.3%.
How much free cash flow does UTMD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $14.69M minus capital expenditures of $371.00K produced free cash flow of $14.32M.
How much debt does Utah Medical Products have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $225.00K and cash and equivalents of $85.76M.
UTMD pages: Overview, Dividends, Earnings, Financials, Valuation, Competitors